Page 16 - Polypid Ltd News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The FDA approved an expansion in the label for Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA's (NASDAQ: SNY) immunotherapy Libtayo for treating patients with advanced basal cell carcinoma previously treated with a hedgehog pathway inhibitor, HHI, or for whom an HHI is not appropriate. Full approval was granted for patients with locally advanced BCC and accelerated approval was granted for patients with metastatic BCC. Moderna Strikes Vaccine Supply Agreements With Taiwan and Columbia Moderna Inc (NASDAQ: MRNA) announced two supply agreements for its COVID-19 Vaccine - one with ...

IPO Lockup Expiration Alert: PolyPid (PYPD) BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - The lockup period of PolyPid Ltd. (PYPD) ends tomorrow, i.e., December 23. PolyPid is a clinical-stage biopharmaceutical company developing prolonged-release therapeutics for surgical site infections using its proprietary PLEX technology. The company's lead product candidate D-PLEX??? is currently in a phase III trial for the prevention of surgical site infections (SSIs) in abdominal surgery, dubbed SHIELD I. The top-line results from this study are expected in the second half of 2021. A second phase III trial o...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. PolyPid Initiates SHIELD II: Second Phase 3 Clinical Trial of D-PLEX₁₀₀ for the Prevention of ... PolyPid Ltd.December 16, 2020 GMT Enrollment in SHIELD I, the First Phase 3 Clinical Trial Continues to Progress, with Top-line Data Anticipated in Second Half of 2021 PETAH TIKVA, Israel, Dec. 16, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its...